Garcia-Echeverria et al (2004) presented a new compound (a pyrrolo[2,3-d] pyrimidine) that although inhibiting the IGF-1R and IR TK equipotently in cell-free systems, exhibited several-fold selectivity for the IGF-1R in a cellular context and reduced the growth of IGF-1R positive fibrosarcomas in vivo. The gene discussed is IGF1R; the disease is fibrosarcoma.